NewCaff™- Microencapsulated caffeine

1. In vitro study on the release of NewCaff™ during digestion
2. Mechanism of action and benefits

An in vitro study carried out by Lipofoods to compare the release of raw, uncapsulated caffeine with micro-encapsulated caffeine NewCaff™ during digestion.

The test simulated the conditions of digestion to mimic the release of caffeine

• in the stomach, with 200 mL of HCl in a 500 mL beaker at 37°C (constant temperature throughout the test) and 2 g of NewCaff™-75 or uncapsulated caffeine.
• in the intestine, with 200 mL of NaHPO4 added to the solution from the first test. The pH was adjusted to 7 with NaO

The samples were then analyzed by high-performance liquid chromatography (3 readings per sample).

The table below shows the gradual release of NewCaff™: by 30 min, only 23.99% of NewCaff™ had been released whereas 100% of the raw caffeine had been released.

The results demonstrate the gradual release of NewCaff™-75 compared to raw, uncapsulated caffeine.

In conclusion, NewCaff™ has a prolonged effect compared with raw caffeine.

This study was also carried out on NewCaff™-60.

The figure below shows the release profiles forNewCaff™-60 and -75 compared with raw caffeine.

Sources:

• Lipofoods, 2014.Release studies NewCaff vs. un-encapsulated Caffeine.
• Lipofoods 2016. Lipofoods. NewCaff Global presentation.

Several studies show that caffeine also plays a role in improving physical performance by favoring the mobilization of lipid reserves as energy sources for working muscles. Caffeine slows the depletion of glycogen, the preferred energy source of muscles, when exercising (Mundt et al., 2008).

Caffeine is rapidly absorbed by the stomach and intestine and circulates in the blood stream, reaching all tissues in the body. The onset of the stimulating effect is thus rapid, but only transitory.

Caffeine is metabolized in the liver by the cytochrome P450 enzyme system into three dimethylxanthine isomers: paraxanthine, theobromine, and theophylline. The main metabolic pathway in humans (70-80%) is via demethylation into paraxanthine catalyzed by the CYP 1A2 cytochrome in the liver. A small proportion is metabolized by the CYP3A4 cytochrome, xanthine oxidase and N-acteyltransferase 2.

The mean half-life of caffeine in the body is 4 h (estimations vary between 2 and 10 h).

In contrast to classic caffeine, NewCaff™ has a controlled release system that prevents the classic caffeine crash.

Caffeine has a bitter taste that makes it unpopular as a supplement in many products.

NewCaff™ masks the bitter taste of caffeine and thus allows its use in many applications.

This scientific opinion of EFSA on caffeine (2015) concludes that consumption of 400 mg of caffeine per day with single doses of up to 200 mg (3 mg/kg body weight (bw) for an adult weighing 70 kg) does not pose any safety concerns for healthy adults (except for pregnant women).

The FDA also concluded that consumption of more than 400 mg of caffeine per day for adults in good health is not associated with harmful or dangerous effects.

Sources:

– EFSA, 2015. Scientific Opinion on the safety of caffeine Tabs. EFSA Journal 2015; 13(5):4102 [120 pp.].
– Lipofoods. NewCaff Global presentation, 2016.
– Synadiet, Ingredient fact sheet: La caféine, 2012.

Micro-encapsulation of caffeine is carried out on a fluidized bed composed of high melting point lipids. The caffeine particles are coated with a mixture of solid and liquid lipids that are sprayed on through a nozzle.
Each particle is uniformly coated to form a smooth coating:

source: Glat GmbH.

This technique ensures the slow release of caffeine and completely masks the bitter taste.

Sensory evaluation using a triangle test has shown that NewCaff™ successfully masks the bitter taste of caffeine.

NewCaff™ can be used in a large range of food products and food supplements: energy powders, bars, gels, chewing gum, confectionery, etc.

Sources:

• Lipofoods. NewCaff Global presentation, 2016.

Five health claims for caffeine have been reviewed and approved by EFSA.

The European Commission published a draft regulation to authorize four health claims for which EFSA concluded that there are no adverse health effects in May 2015. In application of Article 88-4 of the French Constitution regarding EU draft regulations, the text was also submitted to the French National Assembly and Senate.

– Caffeine helps to increase alertness (EFSA, ID 736, 1011, 1187, 1485, 1491, 2063, 2103) *
– Caffeine helps to increase attention (EFSA, ID 736, 1485, 1491, 2375) *
– Caffeine helps to increase endurance performance (EFSA, ID 737, 1486) **
– Caffeine helps to increase endurance capacity** (EFSA, ID 1488)

* The claim cannot be used for food targeting children, including adolescents The claim is authorized for doses of a minimum of 75 mg of caffeine per intake.

** The claim can only be used for food that exclusively targets adults performing endurance exercise. The claim is authorized at doses of 3 mg/kg bw.

These four claims can be used if the consumer is warned not to exceed the recommended daily dose of 400 mg of caffeine, regardless of its source (200 mg for pregnant or breastfeeding women).

The European Commission (EC) rejected the fifth health claim stipulating that caffeine “reduces the rated perceived effort during exercise” for which EFSA concluded that there were no adverse effects [for adults performing endurance exercise] (at doses of 4 mg/kg bw).

The European parliament finally calls on the Commission to withdraw the draft regulation on July 7th 2016. (European Parliament resolution of 7 July 2016)